Sodium Iodide label

Sodium Iodide

Sodium Iodide Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Females of childbearing age and pediatric patients under 18 should not be studied unless the benefits anticipated from the performance of the test outweigh the possible risk of exposure to the amount of ionizing radiation associated with the test.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Sodium Iodide I-123 is indicated for use in the evaluation of thyroid function and/or morphology.

History

There is currently no drug history available for this drug.

Other Information

GE Healthcare (Medi-Physics, Inc.) Sodium Iodide I-123 for diagnostic use is supplied as capsules for oral administration. At calibration time, each capsule has an activity of 3.7 MBq (100 µCi) or 7.4 MBq (200 µCi). Each gelatin capsule contains not more than 20 µg of sodium hydroxide and not more than 1 g of sucrose. Each capsule also contains FD&C Yellow No. 6.

Sodium Iodide I-123 is an odorless compound, freely soluble in water. The I-123 is produced in an accelerator by bombardment of enriched Xe-124 with protons [Xe-124 (p,2n) Cs-123Image from Drug Label ContentXe-123Image from Drug Label Content I-123].

The radionuclidic composition at calibration time is not less than 99.5% I-123 and not more than 0.5% all other nuclides (Te-121, I-125, I-131, I-126, I-124, I-130, I-121 and Na-24). The radionuclidic composition at expiration time is not less than 98.28% I-123 and not more than 1.72% all other nuclides (Te-121, I-125, I-131, I-126, I-124, I-130, I-121 and Na-24).

Molecular formula: Na123I

Molecular Weight: 145.99

Sodium Iodide Manufacturers

  • Ge Healthcare, Medi-physics, Inc.
    Sodium Iodide | Ge Healthcare, Medi-physics, Inc.
    No Recall

    Sodium Iodide | Ge Healthcare, Medi-physics, Inc.

    Sodium Iodide | Ge Healthcare, Medi-physics, Inc.

    The recommended oral dose range for diagnostic studies of thyroid function in the average adult patient (70 kg) is 3.7-14.8 MBq (100-400 µCi) of Sodium Iodide I-123. The lower portion of the range 3.7 MBq (100 µCi) is recommended for uptake studies alone, and the higher portion 14.8 MBq (400 µCi) for thyroid imaging.

    Concentration of I-123 in the thyroid gland should be measured in accordance with standardized procedures. Consideration should be given to the use of proper instrumentation in thyroid imaging with Sodium Iodide I-123. The determination of I-123 concentration in the thyroid gland may be initiated at six hours after administration of the dose.

    Use contents of the capsule up to 24 hours after calibration time and date. Thereafter, discard the capsule with its contents. The user should wear waterproof gloves at all times when handling the capsule.

    The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

  • Mwi (Vetone)
    Sodium Iodide | Mwi (vetone)
    No Recall

    Sodium Iodide | Mwi (vetone)

    Sodium Iodide | Mwi (vetone)

    For intravenous injection only.

    CATTLE: 15 mL/100 lb body weight (30 mg/lb of body weight). Administer slowly, using aseptic procedures. Inject carefully to avoid deposition outside of the vein.  May be repeated at weekly intervals, if necessary.

  • Vettek
    Sodium Iodide | Vettek
    No Recall

    Sodium Iodide | Vettek

    Sodium Iodide | Vettek

    Using aseptic procedures, administer slowly by intravenous injection. Inject carefully to avoid deposition outside of the vein. The usual dose is 30 mg per pound of body weight (15 mL/100 lb). May be repeated at weekly intervals, if necessary.